XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 24 Months Ended 63 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2018
USD ($)
Jul. 31, 2022
USD ($)
Dec. 31, 2018
USD ($)
performanceObligation
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaboration And Other Agreements [Line Items]                    
Revenues   $ 24,496 $ 11,101              
Deferred revenue, current $ 9,249 9,249             $ 9,249 $ 9,988
Deferred revenue, net of current portion 58,006 58,006             58,006 $ 59,480
Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment           $ 150,000        
Potential commercial milestone payments under agreement               $ 330,000    
Potential development and regulatory milestone payments under agreement               435,000    
Development and regulatory milestones recognized 15,000   0           115,000  
Collaborative agreement transaction price               154,000    
Variable consideration recognized               $ 4,000    
Number of performance obligations | performanceObligation               2    
I-Mab | I-Mab Biopharma Collaboration and License Agreement                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment         $ 15,000          
Revenues   0 200              
Development and regulatory milestones recognized   5,000   $ 5,000            
Minimum | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)           15.00%        
Maximum | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)           24.00%        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Revenues           $ 150,000        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities                    
Collaboration And Other Agreements [Line Items]                    
Revenues   15,000                
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                    
Collaboration And Other Agreements [Line Items]                    
Revenues   1,300 300              
RevenuesFromCMOAgreementsMember | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment             $ 10,000      
Annual Fixed Payments 14,400 14,400             14,400  
Revenues   3,600 $ 0              
Deferred revenue 7,800 7,800             7,800  
Deferred revenue, current 7,100 7,100             7,100  
Deferred revenue, net of current portion 700 700             700  
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Annual Fixed Payments 19,500 19,500             19,500  
Additional Payments $ 5,100 $ 5,100             $ 5,100